

# BMJ Open

## Home oxygen therapy reduce risk of hospitalization in patients with chronic obstructive pulmonary disease: A population-based retrospective cohort study, 2005–2012

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-009065
Article Type:	Research
Date Submitted by the Author:	16-Jun-2015
Complete List of Authors:	Cho, Kyoung Hee; Yonsei University, Public Health Kim, Young Sam Nam, Chung Mo; Yonsei University College of Medicine, Biostatistics Kim, Tae Hyun; Graduate School of Public Health, Yonsei University, Department of Hospital Administration Kim, Sun Jung; Yonsei University College of Medicine, Department of Public Health & Institute of Health Services Research Han, Kyu-Tae; Yonsei University College of Medicine, Department of Public Health & Institute of Health Services Research Park, Eun-Cheol; Yonsei University College of Medicine, Department of Preventive Medicine and Institute of Health Services Research
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine, Health services research
Keywords:	Chronic airways disease < THORACIC MEDICINE, Change management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Home oxygen therapy reduces risk of hospitalization in patients with chronic obstructive pulmonary disease: A population-based retrospective cohort study, 2005–2012

Kyoung Hee Cho, RN, MPH<sup>1,2</sup>, Young Sam Kim, MD, PhD<sup>3</sup>, Chung Mo Nam, PhD<sup>4</sup>,  
Tae Hyun Kim, PhD<sup>2,5</sup>, Sun Jung Kim, MHSA<sup>1,2</sup>, Kyu-Tae Han<sup>1,2</sup>,  
Eun-Cheol Park, MD, PhD<sup>2,6\*</sup>

<sup>1</sup> Department of Public Health, Graduate School, Yonsei University, Seoul, Korea

<sup>2</sup> Institute of Health Services Research, College of Medicine, Yonsei University, Seoul, Korea

<sup>3</sup> Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea

<sup>4</sup> Department of Biostatistics, College of Medicine, Yonsei University, Seoul, Korea

<sup>5</sup> Graduate School of Public Health, Yonsei University, Seoul, Korea

<sup>6</sup> Department of Preventive Medicine, College of Medicine, Yonsei University, Seoul, Korea

**Word count:** 2,797 words

\*Correspondence: Eun-Cheol Park

Department of Preventive Medicine and Institute of Health Services Research, Yonsei  
University College of Medicine

50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

Tel: 82-2-2228-1862 FAX: 82-2-392-8133

## Abstract

**Objective:** This study evaluated the effect of home oxygen therapy (HOT) on hospital admissions in chronic obstructive pulmonary disease (COPD) patients.

**Design and setting:** Using nationwide health insurance claims from 2002–2012, we conducted a longitudinal population-based retrospective cohort study.

**Participants:** Individuals who are 40 years or above and newly diagnosed with COPD in 2005.

**Outcome measures:** the primary outcome was total number of hospitalization during study period. Participants were matched using HOT propensity scores and were stratified by respiratory impairment (Grade 1:  $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55\text{mmHg}$ ; Grade 2:  $FEV_1 \leq 30\%$  or  $Pa,O_2$  56-60mmHg; Grade 3:  $FEV_1 \leq 40\%$  or  $Pa,O_2$  61-65mmHg; No grade:  $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), then a negative binomial regression analysis was performed for each group.

**Results:** Of the 36,761 COPD patients included in our study, 1,330 (3.6%) received HOT. In a multivariate analysis of Grade 1 patients performed prior to propensity score matching, the adjusted relative risk of hospitalization for patients who did not receive HOT was 1.27 (95% CI, 1.01–1.60). In a multivariate analysis of Grade 1 patients performed after matching, the adjusted relative risk for patients who did not receive HOT was 1.65 (95% CI, 1.25–2.18). In Grade 2 or Grade 3 patients, no statistical difference in hospital admission risk was detected. In the no grade group of patients, HOT was associated with increased risk of hospitalization.

**Conclusions:** HOT reduces the risk of hospital admission in COPD patients with severe hypoxemia. However, apart from these patients, HOT use is not associated with hospital

admissions, or is more likely to admit.

**Key word:** home oxygen therapy, chronic obstructive pulmonary disease, hospital admission, long-term oxygen therapy

### Strengths and limitations of this study

- We analyzed the association between home oxygen therapy and hospitalization for COPD patients using nationwide claims data and conducted a longitudinal population-based prospective analysis based on claims from 2005 to 2012.
- We were able to increase the homogeneity of our study sample by identifying patients who were newly diagnosed in 2005.
- We made an effort to accurately determine the net effect of HOT via propensity score matching.
- In our findings, there may be potential unmeasured variable bias because we used the data based on claims.

## Introduction

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by progressive airflow limitation that is not fully reversible, causing disability, but is frequently undiagnosed<sup>3</sup>. COPD is a major cause of morbidity and mortality, acting increasingly as a substantial societal burden,<sup>4</sup> hence viewed as a serious public health problem in many countries throughout the world. According to the World Health Organization estimates, 80 million people have moderate to severe COPD, and three million people have died of COPD in 2005. The same estimates also predicted that it will become the fourth leading cause of death by 2030<sup>5</sup>.

In an effort to combat COPD-related hospitalization, researchers have studied the effects of oxygen therapy. Long-term oxygen therapy (LTOT) has been shown to improve survival and quality of life as well as to stabilize pulmonary hypertension in COPD patients<sup>6-11</sup>. In Korea, clinical practitioners and policy-makers began to recognize the benefits of LTOT. Social welfare services for people with respiratory related disabilities in Korea are offered through respiratory impairment<sup>12</sup>. Home oxygen therapy is the administration of oxygen at concentrations greater than the ambient air concentration at home and the cost of such long term oxygen therapy has been included for coverage in the national health insurance system since 2006. However, ambulatory oxygen delivery systems and home ventilator service is not currently covered by the health insurance system. As the burden of COPD continues to increase, analyzing the status of health care utilization in patients with COPD is important in establishing health care plans that encourage proper management of COPD.

Yet it must be taken into account that findings on the effect of home oxygen therapy on

1  
2  
3  
4 hospitalization have varied. Although several studies have indicated that LTOT decreases  
5  
6 hospital admissions<sup>13-16</sup>, one study found no effect on hospital admissions<sup>17</sup>. Most studies that  
7  
8 have found an effect of LTOT on hospital admission have detected the greatest association  
9  
10 among severely hypoxemic COPD patients (Pa,O<sub>2</sub>≤60 mmHg at rest on room air)<sup>13-16</sup>. In  
11  
12 moderately hypoxemic COPD patients (Pa,O<sub>2</sub> 55–70 mmHg at rest on room air: 7.3-9.5 kPa),  
13  
14 HOT may not reduce hospitalizations<sup>17</sup>. Also, regarding oxygen prescription, questions have  
15  
16 recently been raised as hospital admission is more likely in LTOT users and medical costs are  
17  
18 increasing due to the inappropriate use of oxygen<sup>18</sup>.  
19  
20  
21  
22

23 The aim of this study was to assess the effect of HOT on hospital admissions, in which  
24  
25 COPD patients were stratified into forced expiratory volume 1 second or arterial oxygen  
26  
27 tension.  
28  
29  
30  
31  
32

## 33 **Methods**

### 34 *Data and study design*

35  
36  
37 This study used 2002–2012 claims from the Korean National Health Insurance Service  
38  
39 (KNHIS) claims database. We conducted a longitudinal population-based retrospective cohort  
40  
41 study of newly diagnosed adult COPD patients to investigate the association between HOT  
42  
43 and hospital admissions over a 7-year follow-up period. Participants were 40 years of age or  
44  
45 older with newly developed COPD (codes J43.x except for J43.0 or J44.x, International  
46  
47 Classification of Disease, 10<sup>th</sup> edition [ICD-10]). The codes of J44.x and J43.x (except for  
48  
49 J43.0) refer to COPD or emphysema, respectively. J43.0 is McLeod's syndrome. The new  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 diagnosis was confirmed by a lack of COPD-related claims in 2002–2004 and the first  
5  
6 COPD-related claim in 2005. Presence or absence of HOT was analyzed from 2006 and  
7  
8 onwards, and hospital admissions were analyzed from 2007 to 2012. If a patient died during  
9  
10 the study period, we observed hospital admissions until time of death or end of study. Ethical  
11  
12 approval for this study was granted by the institutional review board of the Graduate School  
13  
14 of Public Health, Yonsei University, Seoul, Korea.  
15  
16  
17  
18  
19  
20

### 21 ***Study population***

22  
23  
24 The total number of individuals in 2002–2012 aged 40 years or older with COPD was  
25  
26 1,538,711. Of these patients, 138,680 patients received their diagnosis in 2005 and were still  
27  
28 alive in 2006. We modified the criteria which was used in Kim J. et al.'s study to define  
29  
30 COPD patients using claims data<sup>19</sup>. Hence COPD was defined in the study by the following  
31  
32 criteria: 1) age $\geq$ 40-years-old; 2) ICD-10 codes for COPD (J43.x except for J43.0 and J44.x;  
33  
34 emphysema and COPD, respectively); and 3) use of one or more COPD medications at least  
35  
36 twice per year. Unfortunately, we could not review all of such prescriptions and thus replaced  
37  
38 the third criteria with patients having over four outpatient visits per year due to COPD as the  
39  
40 primary diagnosis. Since we inferred COPD diagnoses from information contained in the  
41  
42 KNHIS claims database, we developed a process to aid in the selection of participants who  
43  
44 actually had COPD. We excluded 101,919 patients who had fewer than four outpatient visits  
45  
46 with COPD as the primary complaint, did not receive HOT, and did not experience a hospital  
47  
48 admission due to COPD during 2006. Our final study sample included 36,761 patients, 1,330  
49  
50 who received HOT and 35,431 who did not.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Variables*

The dependent variable in this study was the total number of hospital admissions during the study period. We defined hospital admission due to COPD as the usage of inpatient medical services for more than 1 day and primary emphysema or COPD by the ICD-10 code of J43.x (except for J43.0) or J44.x.

Covariates considered included age, sex, health insurance status (national health insurance or medical aid), the Charlson comorbidity index (0, 1, or 2<sup>+</sup>)<sup>20</sup>, HOT (yes, no), use of the intensive care unit (ICU) (yes, no), number of hospital admissions (0, 1, or 2<sup>+</sup>), and respiratory impairment (1, 2, 3, or No grade). In Korea, The Ministry of Health and Welfare provides social welfare services to disabled person through the Welfare of Disabled Person Act. However, our government uses strict criteria for certificating a disabled person due to a lack of budget set for disabled people. According to the Welfare of Disabled Person Act, the severity of respiratory impairment is determined by 3 clinical parameters: dyspnea, FEV<sub>1</sub>, and Pa,O<sub>2</sub>. The Criteria corresponding to grade 1 was patients with chronic respiratory failure requiring oxygen therapy and a predicted FEV<sub>1</sub> of  $\leq 25\%$  or a resting Pa,O<sub>2</sub> of  $\leq 55$  mmHg (room air); the criteria corresponding to grade 2 was patients with dyspnea when walking at home and a predicted FEV<sub>1</sub> of  $\leq 30\%$  or Pa,O<sub>2</sub> of 56-60 mmHg (room air); the criteria corresponding to grade 3 was patients with dyspnea when walking at their own pace at ground level and a predicted FEV<sub>1</sub> of  $\leq 40\%$  or Pa,O<sub>2</sub> of 61-65 mmHg (room air). We defined the “No grade” group as patients with unknown FEV<sub>1</sub> or Pa,O<sub>2</sub>. Only the comorbidity component of the Charlson comorbidity index was calculated. All of these variables were measured at the 2006 baseline.



### *Statistical analysis*

First, demographic characteristics of patients who received HOT and those who did not were compared; the chi-square test was used to assess categorical variables, and t-tests were used to assess continuous variables. Next, a non-parsimonious multivariable logistic regression model was used to estimate propensity scores for HOT. Propensity score matching (PSM) is a statistical matching technique that attempts to estimate the effect of a treatment, policy, or other intervention by accounting for the covariates that predict treatment reception. The PSM allows one to design and analyze an observational study so that it mimics certain characteristics of a randomized controlled trial<sup>21</sup>. We included the following in our propensity model: age, sex, health insurance type, Charlson comorbidity index, ICU use, number of hospital admissions in 2006, and respiratory disability grade. The c-statistic for our propensity model was 0.784. Subjects who received HOT were matched on a one-to-one basis with those who did not. Then, we stratified participants according to their respiratory disability grade, based on hypoxemic status, and evaluated the relationship between HOT and hospital admissions in each group using a negative binomial regression analysis, which was chosen due to over-dispersion. All analyses were performed using SAS v9.3.

### **Results**

Of the 36,761 patients in our study, 1,330 (3.6%) received HOT. Prior to propensity score matching, baseline characteristics differed significantly between patients who received HOT and those who did not (Table 1). After propensity score matching, however, only the number of hospital admissions and respiratory disability grade differed between the two groups.

1  
2  
3  
4 Table 2 presents incidence density (ID) rates for hospital admission according to HOT  
5 usage. Prior to propensity score matching, the ID for Grade 1 ( $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55$   
6 mmHg) who received HOT was 0.60 vs. 1.01 for those who did not. However, for patients  
7 with Grade 2 or Grade 3 ( $FEV_1 \leq 30\%$  or  $Pa,O_2$  56-60 mmHg;  $FEV_1 \leq 40\%$  or  $Pa,O_2$  61-65  
8 mmHg) or categorized as “No grade” ( $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), the ID was higher for those  
9 who received HOT than for those who did not (0.61 vs. 0.63; 0.47 vs. 0.46; and 0.34 vs. 0.05,  
10 respectively). Similar results were obtained after propensity score matching. For Grade 1  
11 patients, the ID was lower for patients who received HOT than for those who did not (0.62 vs.  
12 0.79), while in Grade 2/3 or No grade, the ID was higher for patients who received HOT  
13 (0.59 vs. 0.37; 0.47 vs. 0.23; and 0.34 vs. 0.07, respectively).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 Table 3 presents the adjusted relative risk (RR) for hospital admission prior to propensity  
28 score matching. After controlling for all covariates, the adjusted RR for Grade 1 patients who  
29 did not receive HOT compared to the reference group (those who did receive HOT) was 1.12  
30 (95% CI, 1.01–1.60). The RR for Grade 2 patients was 0.96, but this difference was not  
31 statistically significant. In Grade 3 or No grade, the adjusted RRs for patients who did not  
32 receive HOT were less than one (RR, 0.74; 95% CI, 0.58–0.93; RR, 0.65; 95% CI, 0.60–0.70,  
33 respectively).  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 After propensity score matching, the adjusted RR for Grade 1 patients who did not receive  
44 HOT was 1.65 (95% CI, 1.25–2.18); in Grade 2 patients, the adjusted RR was 1.07 (95% CI,  
45 0.80–1.43); in Grade 3 patients, the adjusted RR was 0.72 (95% CI, 0.51–1.02); and in  
46 patients without a grade, the adjusted RR was 0.73 (95% CI, 0.62–0.86) (Table 4).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

We found that HOT was associated with a 27% decreased risk of hospitalization in Grade 1 COPD patients ( $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55$  mmHg) prior to propensity score matching and a 65% decreased risk after matching. However, apart from Grade 1 patients, the use of HOT did not show a statistically significant association with hospital admission prior to or after matching in Grade 2 patients. Also, in Grade 3 or No grade COPD patients ( $FEV_1 \leq 40\%$  or  $Pa,O_2 \leq 65$  mmHg;  $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), HOT was associated with an increased risk of hospital admission prior to propensity score matching and in the case of No grade patients, HOT was still associated with an increased risk of admission after propensity score matching.

In Korea, HOT can be prescribed by a pulmonologist as well as an internist and a thoracic surgery specialist through only a one time test of arterial blood gas analysis; similar to the criteria that most countries use for home oxygen therapy, the indications of HOT for reimbursement are patients with  $Pa,O_2$  less than or equal to 55mmHg or with  $SpO_2$  less than or equal to 88%. Patients with  $Pa,O_2$  between 56 and 60mmHg or  $SpO_2$  below 89%, must also have congestive heart failure, polycythemia (hematocrit $>55\%$ ), or pulmonary hypertension to qualify during the stable period after 3 months of internal treatment. Physicians can prescribe patients with Grade 1 or Grade 2 respiratory impairment without conducting any other tests. If patients without indication of such grade receives HOT prescriptions, it means that the patient was seen by a physician under the COPD code but that the patient did not fill out the necessary form to receive an assigned grade. Hence the patient's clinical status fits the indications for HOT prescription, meaning that these patients may in actuality, have any of the grades described above, including Grade 1. Therefore, in the case of patients without a grade, the use of HOT means that the patients who use such HOT

1  
2  
3  
4 may have conditions that are clinically more severe than those who do not use HOT.  
5  
6

7 Our results are comparable to the findings of previous studies. Most previous studies have  
8 showed a consistent tendency in patients with severe hypoxemia ( $\text{Pa,O}_2 < 8.0$  kPa) in which  
9 HOT was associated with decreased hospital admissions. However, Ringbaek et al. found that  
10 home oxygen therapy did not reduce hospitalization in patients with moderate hypoxemia  
11 ( $\text{Pa,O}_2 > 8.0$  kPa)<sup>17</sup>. In addition, Turner et al. recently suggested that oxygen use outside the  
12 National Institute for Health and Care Excellence (NICE) guidance did not appear to prevent  
13 admissions<sup>18</sup>. In South Korea, although HOT is used according to NICE guidelines, HOT was  
14 not associated with decreased risk of hospital admission even in Grade 2 ( $\text{Pa,O}_2$  56-60mmHg).  
15 In Grade 3 or No grade patients, admission to hospitals was more likely in HOT users prior to  
16 matching instead, and after matching, there was no statistically significant difference in  
17 Grade 3 patients. There are two possible explanations regarding this result. One is that  
18 because admission for exacerbation is more common in severe COPD<sup>22</sup> patients and in  
19 oxygen users<sup>23</sup>, hospital admissions are more frequently expected in HOT users if patients'  
20 severity is unequal as they have more severe lung disease. The second possibility may be  
21 explained through residual confounding. Garcia-Aymerich J. et al. showed that the risks of re-  
22 admission was high in LTOT users after adjustment for severity variables such as FEV<sub>1</sub> or  
23  $\text{Pa,O}_2$ <sup>24</sup>. The authors explained these paradoxical results using residual confounding, that the  
24 excess risk of COPD re-admission associated with medical care related factors might be  
25 partially due to confounding by indication. Our finding supports that HOT use reduces  
26 hospitalization in COPD patients with severe hypoxemia ( $\text{Pa,O}_2 \leq 55$  mmHg). However,  
27 although HOT may improve quality of life and help breathing during activities in COPD  
28 patients without severe hypoxemia, use of HOT should be considered to prevent hospital  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1  
2  
3  
4 admissions in COPD patients with  $\text{Pa,O}_2 > 55 \text{ mmHg}$ . We need to at least conduct further  
5  
6 research about cost-effectiveness for HOT use in these patients and then, if necessary, require  
7  
8 modification of the criteria for HOT prescription.  
9

10  
11 This study has several limitations. First, because we used claims data, which are based on  
12  
13 information in the KNHIS, we were not able to assess some factors that could potentially  
14  
15 influence hospital admissions. For example, we had no data on smoking history, body mass  
16  
17 index, health behaviors, use of systematic corticosteroids, laboratory results, etc. Second, we  
18  
19 categorized respiratory impairment into four respiratory disability grades, as determined by  
20  
21  $\text{FEV}_1$ ,  $\text{Pa,O}_2$ , and dyspnea. Therefore, we did not use quantitative  $\text{FEV}_1$  or  $\text{Pa,O}_2$  values,  
22  
23 instead estimating a patient's hypoxemic status. Especially in the No grade group, it is  
24  
25 possible that patients with various severities have been mixed together. The third limitation is  
26  
27 the accuracy of our COPD diagnosis. The accuracy of diagnoses in KNHIS claims data is  
28  
29 roughly 70%<sup>25</sup>. To increase accuracy, a review of all prescriptions would be required.  
30  
31 Unfortunately, we could not perform such a review here. However, the accuracy of COPD  
32  
33 diagnoses in this study may have been compromised. The fourth limitation involves the  
34  
35 definition of newly diagnosed patients. In this study, newly diagnosed patients were defined  
36  
37 as those who did not have COPD claims in 2002–2004 but did have a COPD claim in 2005.  
38  
39 Thus, patients diagnosed prior to 2002 who did not utilize COPD-related medical services in  
40  
41 2002–2004 may have been included in the sample. The final limitation is related to patterns  
42  
43 of HOT use. Although all of our study subjects used HOT in or after 2006 and we adjusted  
44  
45 for the number of hospital admission at baseline, because of considering hypothesis in  
46  
47 previous studies that an effect of oxygen therapy in patients who start home oxygen therapy  
48  
49 as outpatients are less likely to be derived from a “regression to the mean phenomenon”<sup>14</sup>, we  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 did not know the duration of usage per day, whether use was continuous or non-continuous,  
5  
6 or whether patient compliance was good.  
7

8  
9 Despite these limitations, our study has several strengths. First, we analyzed COPD  
10 patients using nationwide claims data and conducted a longitudinal population-based  
11 prospective analysis based on claims from 2005 to 2012. Our study population was relatively  
12 large and our follow-up period was relatively long compared to previous studies evaluating  
13 the association between oxygen therapy and hospitalization<sup>1,2</sup>. Second, we were able to  
14 increase the homogeneity of our study sample by identifying patients who were newly  
15 diagnosed in 2005. We could observe the progression of their disease over time via hospital  
16 admissions. Finally, we made an effort to accurately determine the net effect of HOT via  
17 propensity score matching.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 In conclusion, HOT reduces hospital admission risk in COPD patients with severe  
31 hypoxemia. However, except for these patients, HOT use is not associated with hospital  
32 admissions, or an increase in the likeliness of hospital admission. Still, further research on  
33 cost-effectiveness of HOT in patients who does not meet the indication for HOT is needed,  
34 even in patients with Pa,O<sub>2</sub> 56-60 mmHg who meet the indication.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

#### 45 **Acknowledgement**

46  
47 **Financial Disclosure:** The entire study was conducted without external funding.  
48  
49

50  
51 **Conflicts of Interests:** None of the authors have any conflicts of interest associated with this  
52 study.  
53  
54  
55

1  
2  
3  
4 **Contribution** : Cho KH and Park EC carried out constructing study design, Cho KH and  
5  
6 Nam CM carried out analyzing data, Cho KH, Park EC, and KimYS interpreted results, Kim  
7  
8 YS was scientific advisor, Park EC guided and directed this study Cho KH and Kim TH  
9  
10 wrote manuscript and Kim SJ and Han KT was clinical investigators.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## References

1. Kessler R, Faller M, Fourgaut G, Menecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1999;159:158-64.
2. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? *Eur Respir J.* 2002;20:38-42.
3. Jung JY, Kang YA, Park MS, Oh YM, Park EC, Kim HR, et al. Chronic obstructive lung disease-related health care utilisation in Korean adults with obstructive lung disease. *Int J Tuberc Lung Dis* 2011;15:824-9.
4. Halpin DM, Miravittles M. Chronic obstructive pulmonary disease: the disease and its burden to society. *Proc Am Thorac* 2006;3:619-23.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006;3:e442.
6. Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. *Respir Med* 2008;102:512-8.
7. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Espana PP, et al.



- 1  
2  
3  
4 Predictors of mortality in patients with stable COPD. *J Gen Intern Med*  
5 2008;23:1829-34.  
6  
7  
8  
9  
10  
11 8. Law S, Boyd S, Macdonald J, Raeside D, Anderson D. Predictors of survival in  
12 patients with chronic obstructive pulmonary disease receiving long-term oxygen  
13 therapy. *BMJ Support Palliat Care* Published Online First 2014;25 Mar 2014. doi:  
14 10.1136/bmjspcare-2012-000432.  
15  
16  
17  
18  
19  
20  
21 9. Eaton T, Lewis C, Young P, Kennedy Y, Garrett JE, Kolbe J. Long-term oxygen  
22 therapy improves health-related quality of life. *Respir Med*. 2004;98:285-93.  
23  
24  
25  
26  
27  
28 10. Medical Research Council. Long term domiciliary oxygen therapy in chronic hypoxic  
29 cor pulmonale complicating chronic bronchitis and emphysema. Report of the  
30 Medical Research Council Working Party. *Lancet* 1981;28:681-6.  
31  
32  
33  
34  
35  
36  
37 11. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in  
38 hypoxemia chronic obstructive lung disease. *Ann Intern Med* 1980;93:391-8.  
39  
40  
41  
42  
43 12. Korea Ministry of Government Legislation. Welfare of Disabled Person Act (2011-91).  
44 [http://www.mw.go.kr/front\\_new/policy/index.jsp?PAR\\_MENU\\_ID=06&MENU\\_ID=](http://www.mw.go.kr/front_new/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=063701&PAGE=11)  
45 [063701&PAGE=11](http://www.mw.go.kr/front_new/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=063701&PAGE=11).  
46  
47  
48  
49  
50  
51 13. Clini E, Vitacca M, Foglio K, Simoni P, Ambrosino N. Long-term home care  
52 programmes may reduce hospital admissions in COPD with chronic hypercapnia. *Eur*  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 Respir J 1996;9:1605-10.  
5  
6  
7  
8  
9 14. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce  
10 hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J  
11 2002;20:38-42.  
12  
13  
14  
15  
16  
17 15. Roselle S, D'Amico FJ. The effect of home respiratory therapy on hospital  
18 readmission rates of patients with chronic obstructive pulmonary disease. Respir Care  
19 1982;27:1194-9.  
20  
21  
22  
23  
24  
25 16. Stewart BN, Hood CI, Block AJ. Long-term results of continuous oxygen therapy at  
26 sea level. Chest 1975;68:486-92.  
27  
28  
29  
30  
31  
32 17. Ringbaek TJ, Fabricius P, Lange P. The effect of home oxygen therapy on  
33 hospitalization in moderate hypoxaemic COPD. Chron Respir Dis 2005;2:107-8.  
34  
35  
36  
37  
38 18. Turner AM, Sen S, Steeley C, Khan Y, Sweeney P, Richards Y, et al. Evaluation of  
39 oxygen prescription in relation to hospital admission rate in patients with chronic  
40 obstructive pulmonary disease. BMC Pulm Med 2014;14.  
41  
42  
43  
44  
45  
46 19. Kim J, Kim K, Kim Y, Yoo KH, Lee CK, Yoon HK, et al. The association between  
47 inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed  
48 COPD patients. Respir Med 2014;108:153-61.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med care* 2005;43:1130-9.
21. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res* 2011;46:399-424.
22. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *M Engl J Med* 2010;363:1128-38.
23. Bahadori K, FitzGerald JM, Levy RD, Fera T, Swiston J. Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. *Can Respir J* 2009;16:e43-9.
24. Garcia-Aymerich J, Marrades RM, Monsó E, Barreiro E, Farrero E, Antó JM. Paradoxical results in the study of risk factors of chronic obstructive pulmonary disease (COPD) re-admission. *Respir Med* 2004;98:851-7.
25. Kim RY. Introduction of national patients sample data of Korean Health Insurance Review and Assessment Service. *Forum* 2011.

Table 1. Baseline characteristics of the study sample, stratified according to use of home oxygen therapy

Characteristics	Pre-match (N=36,761)		P-value	Post-match (N=2,478)		P-value
	Yes, n (%)	No, n (%)		Yes, n (%)	No, n (%)	
No Grade	936 (2.6)	34,825 (94.4)		936 (49.2)	1,542 (61.8)	
Age (years), mean (SD)	67.1 (9.6)	63.8 (12.0)	<0.0001	67.4 (9.7)	68.0 (9.9)	0.14
Sex						
Male	964 (4.7)	19,353 (95.3)	<0.0001	884 (49.2)	912 (50.8)	0.21
Female	367 (2.2)	16,078 (97.8)		355 (52.0)	327 (48.0)	
Health insurance type						
National health insurance	1,279 (3.8)	32,645 (96.2)	<0.0001	1,188 (50.5)	1,163 (49.5)	0.02
Medical aid	51 (1.8)	2,786 (98.2)		51 (40.2)	76 (59.8)	
Charlson comorbidity index *						
0	692 (6.5)	9,983 (93.5)	<0.0001	628 (48.4)	670 (51.6)	0.13
1	62 (5.7)	1,021 (94.3)		57 (47.1)	64 (52.9)	
≥2	576 (2.3)	24,427 (97.7)		554 (52.3)	505 (47.7)	
ICU use						
Yes	11 (6.9)	148 (93.1)	<0.0001	9 (39.1)	12 (60.9)	0.30
No	1,319 (3.6)	35,283 (96.4)		1,230 (50.1)	1,225 (49.9)	
Number of hospital admission						
0	1,147 (3.5)	31,923 (96.5)	<0.0001	1,067 (51.5)	1,004 (48.5)	0.002
1	127 (4.9)	2,486 (95.1)		119 (40.6)	174 (59.4)	
≥2	56 (5.2)	1,022 (94.8)		53 (46.5)	61 (53.5)	
Respiratory impairment rating						
Grade 1 (FEV <sub>1</sub> %≤25 or Pa,O <sub>2</sub> ≤55 mmHg)	163 (43.2)	214 (56.8)	<0.0001	91 (43.1)	120 (56.9)	0.001
Grade 2 (FEV <sub>1</sub> %≤30 or Pa,O <sub>2</sub> ≤60 mmHg)	121 (35.6)	219 (64.4)		102 (55.7)	81 (44.3)	
Grade 3 (FEV <sub>1</sub> %≤40 or Pa,O <sub>2</sub> ≤65 mmHg)	110 (26.6)	304 (73.4)		110 (61.1)	70 (38.9)	
No Grade	936 (2.6)	34,694 (97.4)		936 (49.2)	968 (50.8)	

SD, standard deviation; ICU, intensive care unit.

\*, calculated comorbidity component; subtracted age scores.

Table 2. Incidence density for hospital admission according to use of home oxygen therapy

Respiratory Impairment Rating <sup>†</sup>	Pre-match				Post-match (1:1)				
	Yes	No	Yes	No	Yes	No	Yes	No	
	N=1,330	N=35,431	ID*	ID*	N=1,239	N=1,239	ID*	ID*	
Grade 1	Total number of hospital admission	416	748	0.60	1.01	244	319	0.62	0.79
	Person-years	694.1	743.3			390.8	406.0		
Grade 2	Total number of hospital admission	358	601	0.61	0.63	291	128	0.59	0.37
	Person-years	585.6	953.4			495.9	341.4		
Grade 3	Total number of hospital admission	245	672	0.47	0.46	245	81	0.47	0.23
	Person-years	517.8	1455.4			517.8	348.3		
No Grade	Total number of hospital admission	1409	9286	0.34	0.05	1409	322	0.34	0.07
	Person-years	4123.0	18455.3			4123.0	4837.3		

\*ID, Incidence Density; calculated total number of hospital admissions divided into sum of person-years.

<sup>†</sup>, Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>o</sub>2 ≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤ 30% predicted or Pa<sub>o</sub>2 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>o</sub>2 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>o</sub>2 unknown .

Table 3. Relative Risk for hospital admission, stratified respiratory disability grade calculated using negative binomial regression model

Characteristics	Relative Risk (95% CI)							
	Grade 1		Grade 2		Grade 3		No Grade	
Age (years)	1.002	(0.993-1.010)	0.992	(0.983-1.001)	1.010	(0.993-1.021)	1.006	(1.004-1.009)***
Sex								
Male	1.06	(0.87-1.29)	1.25	(0.96-1.62)	0.94	(0.75-1.18)	1.16	(1.10-1.23)***
Female	1.00		1.00		1.00		1.00	
Health insurance type								
National health insurance	1.00	(0.80-1.25)	0.94	(0.75-1.17)	0.60	(0.49-0.75)***	0.69	(0.65-0.73)***
Medical aid	1.00		1.00		1.00		1.00	
Home oxygen therapy								
Yes	1.00		1.00		1.00		1.00	
No	1.27	(1.01-1.60)*	0.96	(0.75-1.22)	0.74	(0.58-0.93)*	0.65	(0.60-0.70)***
Charlson comorbidity index <sup>†</sup>								
0	1.00		1.00		1.00		1.00	
1	0.86	(0.66-1.13)	1.00	(0.72-1.39)	0.82	(0.57-1.17)	1.00	(0.93-1.07)
≥2	1.12	(0.84-1.49)	1.11	(0.81-1.53)	0.90	(0.67-1.21)	1.11	(1.02-1.21)*
ICU use								
Yes	1.13	(0.74-1.70)	1.05	(0.42-2.59)	0.31	(0.09-1.09)	1.02	(0.82-1.27)
No	1.00		1.00		1.00		1.00	
Number of hospital admission								
0	1.00		1.00		1.00		1.00	
1	1.65	(1.29-2.11)***	1.45	(1.12-1.88)**	1.24	(0.98-1.57)	1.69	(1.58-1.81)***
≥2	1.73	(1.34-2.24)***	1.48	(1.11-1.96)**	1.65	(1.28-2.12)***	2.04	(1.88-2.21)***

\*, P-value<0.05; \*\*, P-value<0.01; \*\*\*, P-value<0.001.

Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>2</sub>O<sub>2</sub> ≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤ 30% predicted or Pa<sub>2</sub>O<sub>2</sub> 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>2</sub>O<sub>2</sub> 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>2</sub>O<sub>2</sub> unknown

<sup>†</sup>, calculated comorbidity component; subtracted age scores.

Table 4. Relative risk for hospital admission after propensity score matching calculated using negative binomial regression model

Characteristics	Relative Risk (95% CI)			
	Grade 1	Grade 2	Grade 3	No Grade
Home oxygen therapy				
Yes	1.00	1.00	1.00	1.00
No	1.65 (1.25-2.18) <sup>***</sup>	1.07 (0.80-1.43)	0.72 (0.51-1.02)	0.73 (0.62-0.86) <sup>***</sup>

<sup>\*</sup>, P-value<0.05; <sup>\*\*</sup>, P-value<0.01; <sup>\*\*\*</sup>, P-value<0.001

Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>2</sub>O<sub>2</sub> ≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤30% predicted or Pa<sub>2</sub>O<sub>2</sub> 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>2</sub>O<sub>2</sub> 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>2</sub>O<sub>2</sub> unknown

# BMJ Open

## Home oxygen therapy reduces risk of hospitalization in patients with chronic obstructive pulmonary disease: A population-based retrospective cohort study, 2005–2012

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009065.R1
Article Type:	Research
Date Submitted by the Author:	16-Oct-2015
Complete List of Authors:	Cho, Kyoung Hee; Yonsei University College of Medicine, Department of Public Health & Institute of Health Services Research Kim, Young Sam; Yonsei University College of Medicine, Department of Internal Medicine Nam, Chung Mo; Yonsei University College of Medicine, Biostatistics & Institute of Health Services Research Kim, Tae Hyun; Graduate School of Public Health, Yonsei University, Department of Hospital Administration & Institute of Health Services Research Kim, Sun Jung; Yonsei University College of Medicine, Department of Public Health & Institute of Health Services Research Han, Kyu-Tae; Yonsei University College of Medicine, Department of Public Health & Institute of Health Services Research Park, Eun-Cheol; Yonsei University College of Medicine, Department of Preventive Medicine and Institute of Health Services Research
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine, Health services research
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, PRIMARY CARE

SCHOLARONE™  
Manuscripts



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Home oxygen therapy reduces risk of hospitalization in patients with chronic obstructive pulmonary disease: A population-based retrospective cohort study, 2005–2012

Kyoung Hee Cho, RN, MPH<sup>1,2</sup>, Young Sam Kim, MD, PhD<sup>3</sup>, Chung Mo Nam, PhD<sup>4</sup>,  
Tae Hyun Kim, PhD<sup>2,5</sup>, Sun Jung Kim, MHSA<sup>1,2</sup>, Kyu-Tae Han<sup>1,2</sup>,  
Eun-Cheol Park, MD, PhD<sup>2,6\*</sup>

<sup>1</sup> Department of Public Health, Graduate School, Yonsei University, Seoul, Korea

<sup>2</sup> Institute of Health Services Research, College of Medicine, Yonsei University, Seoul, Korea

<sup>3</sup> Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea

<sup>4</sup> Department of Biostatistics, College of Medicine, Yonsei University, Seoul, Korea

<sup>5</sup> Graduate School of Public Health, Yonsei University, Seoul, Korea

<sup>6</sup> Department of Preventive Medicine, College of Medicine, Yonsei University, Seoul, Korea

**Word count:** 2,797 words

\*Correspondence: Eun-Cheol Park

Department of Preventive Medicine and Institute of Health Services Research, Yonsei  
University College of Medicine

50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

Tel: 82-2-2228-1862 FAX: 82-2-392-8133

## Abstract

**Objective:** This study evaluated the effect of home oxygen therapy (HOT) on hospital admissions in chronic obstructive pulmonary disease (COPD) patients.

**Design and setting:** Using nationwide health insurance claims from 2002–2012, we conducted a longitudinal population-based retrospective cohort study.

**Participants:** Individuals who are 40 years or above and newly diagnosed with COPD in 2005.

**Outcome measures:** the primary outcome was total number of hospitalization during study period. Participants were matched using HOT propensity scores and were stratified by respiratory impairment (Grade 1:  $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55\text{mmHg}$ ; Grade 2:  $FEV_1 \leq 30\%$  or  $Pa,O_2$  56-60mmHg; Grade 3:  $FEV_1 \leq 40\%$  or  $Pa,O_2$  61-65mmHg; No grade:  $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), then a negative binomial regression analysis was performed for each group.

**Results:** Of the 36,761 COPD patients included in our study, 1,330 (3.6%) received HOT. In a multivariate analysis of Grade 1 patients performed prior to propensity score matching, the adjusted relative risk of hospitalization for patients who did not receive HOT was 1.27 (95% CI, 1.01–1.60). In a multivariate analysis of Grade 1 patients performed after matching, the adjusted relative risk for patients who did not receive HOT was 1.65 (95% CI, 1.25–2.18). In Grade 2 or Grade 3 patients, no statistical difference in hospital admission risk was detected. In the no grade group of patients, HOT was associated with increased risk of hospitalization.

**Conclusions:** HOT reduces the risk of hospital admission in COPD patients with severe hypoxemia. However, apart from these patients, HOT use is not associated with hospital

1  
2  
3  
4 admissions, or is more likely to admit.  
5  
6

7 **Key word:** home oxygen therapy, chronic obstructive pulmonary disease, hospital admission,  
8 long-term oxygen therapy  
9

### 10 11 12 **Strengths and limitations of this study** 13

14 • We analyzed the association between home oxygen therapy and hospitalization for  
15 COPD patients using nationwide claims data and conducted a longitudinal population-based  
16 prospective analysis based on claims from 2005 to 2012.  
17  
18

19 • We were able to increase the homogeneity of our study sample by identifying  
20 patients who were newly diagnosed in 2005.  
21  
22

23 • We made an effort to accurately determine the net effect of HOT via propensity score  
24 matching.  
25  
26

27 • In our findings, there may be potential unmeasured variable bias because we used the  
28 data based on claims.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by progressive airflow limitation that is not fully reversible, causing disability, but is frequently undiagnosed [1]. COPD is a major cause of morbidity and mortality, acting increasingly as a substantial societal burden,[2] hence viewed as a serious public health problem in many countries throughout the world. According to the World Health Organization estimates, 80 million people have moderate to severe COPD, and three million people have died of COPD in 2005. The same estimates also predicted that it will become the fourth leading cause of death by 2030[3].

In an effort to combat COPD-related hospitalization, researchers have studied the effects of oxygen therapy. Long-term oxygen therapy (LTOT) has been shown to improve survival and quality of life as well as to stabilize pulmonary hypertension in COPD patients[4-9]. In Korea, clinical practitioners and policy-makers began to recognize the benefits of LTOT. Social welfare services for people with respiratory related disabilities in Korea are offered through respiratory impairment[10]. Home oxygen therapy is the administration of oxygen at concentrations greater than the ambient air concentration at home and the cost of such long term oxygen therapy has been included for coverage in the national health insurance system since 2006. However, ambulatory oxygen delivery systems and home ventilator service is not currently covered by the health insurance system. As the burden of COPD continues to increase, analyzing the status of health care utilization in patients with COPD is important in establishing health care plans that encourage proper management of COPD. These issues are raised in Korea as well as in many countries which the burden of COPD is increasing, and a guideline of indication of home oxygen therapy is needed.

1  
2  
3  
4 Yet it must be taken into account that findings on the effect of home oxygen therapy on  
5 hospitalization have varied. Although several studies have indicated that LTOT decreases  
6 hospital admissions[11-14], one study found no effect on hospital admissions[15]. Most  
7 studies that have found an effect of LTOT on hospital admission have detected the greatest  
8 association among severely hypoxemic COPD patients ( $\text{Pa}_a\text{O}_2 \leq 60$  mmHg at rest on room  
9 air)[11-14]. In moderately hypoxemic COPD patients ( $\text{Pa}_a\text{O}_2$  55–70 mmHg at rest on room  
10 air: 7.3-9.5 kPa), HOT may not reduce hospitalizations[15]. Also, regarding oxygen  
11 prescription, questions have recently been raised as hospital admission is more likely in  
12 LTOT users and medical costs are increasing due to the inappropriate use of oxygen[16].  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 The aim of this study was to assess the effect of HOT on hospital admissions, in which  
26 COPD patients were stratified into forced expiratory volume 1 second or arterial oxygen  
27 tension, and to provide evidence about the appropriate indication of home oxygen therapy.  
28  
29  
30  
31  
32  
33  
34

## 35 **Methods**

### 36 *Data and study design*

37  
38  
39  
40  
41 This study used 2002–2012 claims from the Korean National Health Insurance Service  
42 (KNHIS) claims database. We conducted a longitudinal population-based retrospective cohort  
43 study of newly diagnosed adult COPD patients to investigate the association between HOT  
44 and hospital admissions over a 7-year follow-up period. Participants were 40 years of age or  
45 older with newly developed COPD (codes J43.x except for J43.0 or J44.x, International  
46 Classification of Disease, 10<sup>th</sup> edition [ICD-10]). The codes of J44.x and J43.x (except for  
47 J43.0) refer to COPD or emphysema, respectively. J43.0 is McLeod's syndrome. The new  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 diagnosis was confirmed by a lack of COPD-related claims in 2002–2004 and the first  
5  
6 COPD-related claim in 2005. Presence or absence of HOT was analyzed from 2006 and  
7  
8 onwards, and hospital admissions were analyzed from 2007 to 2012. If a patient died during  
9  
10 the study period, we observed hospital admissions until time of death or end of study. Ethical  
11  
12 approval for this study was granted by the institutional review board of the Graduate School  
13  
14 of Public Health, Yonsei University, Seoul, Korea.

### 21 ***Study population***

22  
23  
24 The total number of individuals in 2002–2012 aged 40 years or older with COPD was  
25  
26 1,538,711. Of these patients, 138,680 patients received their diagnosis in 2005 and were still  
27  
28 alive in 2006. We modified the criteria which was used in Kim J. et al.'s study to define  
29  
30 COPD patients using claims data[17]. Hence COPD was defined in the study by the  
31  
32 following criteria: 1) age $\geq$ 40-years-old; 2) ICD-10 codes for COPD (J43.x except for J43.0  
33  
34 and J44.x; emphysema and COPD, respectively); and 3) use of one or more COPD  
35  
36 medications at least twice per year. Unfortunately, we could not review all of such  
37  
38 prescriptions and thus replaced the third criteria with patients having over four outpatient  
39  
40 visits per year due to COPD as the primary diagnosis. Since we inferred COPD diagnoses  
41  
42 from information contained in the KNHIS claims database, we developed a process to aid in  
43  
44 the selection of participants who actually had COPD. We excluded 101,919 patients: 1) 9,566  
45  
46 patients were dead in 2005; 2) 92,353 patients who had fewer than four outpatient visits with  
47  
48 COPD as the primary complaint, did not receive HOT, and did not experience a hospital  
49  
50 admission due to COPD during 2006. In the exclusion criteria, we arbitrary determined cut  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 off points at outpatient visits were less than 4 times based on a previous study. In the previous  
5  
6 study, the mean value of outpatient visits were 7.4 time for COPD patients in 2009. The mean  
7  
8 value of outpatient visits was 3.2 times in 2005 in our sample. Thus we determined our cut  
9  
10 off points by considering these points. Our final study sample included 36,761 patients, 1,330  
11  
12 who received HOT and 35,431 who did not.

### 13 14 15 16 *Variables*

17  
18  
19 The dependent variable in this study was the total number of hospital admissions due to  
20  
21 COPD during the study period. We defined hospital admission due to COPD as the usage of  
22  
23 inpatient medical services for more than 1 day and primary emphysema or COPD by the  
24  
25 ICD-10 code of J43.x (except for J43.0) or J44.x.

26  
27  
28  
29 Covariates considered included age, sex, health insurance status (national health insurance  
30  
31 or medical aid), the Charlson comorbidity index (0, 1, or 2<sup>+</sup>)[18], HOT (yes, no), use of the  
32  
33 intensive care unit (ICU) (yes, no), number of hospital admissions (0, 1, or 2<sup>+</sup>), and  
34  
35 respiratory impairment (1, 2, 3, or No grade). In Korea, The Ministry of Health and Welfare  
36  
37 provides social welfare services to disabled person through the Welfare of Disabled Person  
38  
39 Act. However, our government uses strict criteria for certificating a disabled person due to a  
40  
41 lack of budget set for disabled people. According to the Welfare of Disabled Person Act, the  
42  
43 severity of respiratory impairment is determined by 3 clinical parameters: dyspnea, FEV<sub>1</sub>,  
44  
45 and Pa,O<sub>2</sub>. The Criteria corresponding to grade 1 was patients with chronic respiratory failure  
46  
47 requiring oxygen therapy and a predicted FEV<sub>1</sub> of ≤25% or a resting Pa,O<sub>2</sub> of ≤55 mmHg  
48  
49 (room air); the criteria corresponding to grade 2 was patients with dyspnea when walking at  
50  
51 home and a predicted FEV<sub>1</sub> of ≤ 30% or Pa,O<sub>2</sub> of 56-60 mmHg (room air); the criteria  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 corresponding to grade 3 was patients with dyspnea when walking at their own pace at  
5 ground level and a predicted FEV<sub>1</sub> of ≤40% or Pa,O<sub>2</sub> of 61-65 mmHg (room air). We defined  
6 the “No grade” group as patients with unknown FEV<sub>1</sub> or Pa,O<sub>2</sub>. Only the comorbidity  
7 component of the Charlson comorbidity index was calculated. All of these variables were  
8 measured at the 2006 baseline.  
9  
10  
11  
12  
13

### 14 15 16 *Statistical analysis* 17

18  
19 First, demographic characteristics of patients who received HOT and those who did not  
20 were compared; the chi-square test was used to assess categorical variables, and t-tests were  
21 used to assess continuous variables. Next, a non-parsimonious multivariable logistic  
22 regression model was used to estimate propensity scores for HOT. Propensity score matching  
23 (PSM) is a statistical matching technique that attempts to estimate the effect of a treatment,  
24 policy, or other intervention by accounting for the covariates that predict treatment reception.  
25 The PSM allows one to design and analyze an observational study so that it mimics certain  
26 characteristics of a randomized controlled trial[19]. We included the following in our  
27 propensity model: age, sex, health insurance type, Charlson comorbidity index, ICU use,  
28 number of hospital admissions in 2006, and respiratory disability grade. The c-statistic for  
29 our propensity model was 0.784. Subjects who received HOT were matched on a one-to-one  
30 basis with those who did not. Then, we stratified participants according to their respiratory  
31 disability grade, based on hypoxemic status, and evaluated the relationship between HOT and  
32 hospital admissions in each group using a negative binomial regression analysis, which was  
33 chosen due to over-dispersion. All analyses were performed using SAS v9.3.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Results

Of the 36,761 patients in our study, 1,330 (3.6%) received HOT. Prior to propensity score matching, baseline characteristics differed significantly between patients who received HOT and those who did not (Table 1). After propensity score matching, however, only the number of hospital admissions and respiratory disability grade differed between the two groups.

Table 2 presents incidence density (ID) rates for hospital admission according to HOT usage. Prior to propensity score matching, the ID for Grade 1 ( $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55$  mmHg) who received HOT was 0.60 vs. 1.01 for those who did not. However, for patients with Grade 2 or Grade 3 ( $FEV_1 \leq 30\%$  or  $Pa,O_2$  56-60 mmHg;  $FEV_1 \leq 40\%$  or  $Pa,O_2$  61-65 mmHg) or categorized as “No grade” ( $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), the ID was higher for those who received HOT than for those who did not (0.61 vs. 0.63; 0.47 vs. 0.46; and 0.34 vs. 0.05, respectively). Similar results were obtained after propensity score matching. For Grade 1 patients, the ID was lower for patients who received HOT than for those who did not (0.62 vs. 0.79), while in Grade 2/3 or No grade, the ID was higher for patients who received HOT (0.59 vs. 0.37; 0.47 vs. 0.23; and 0.34 vs. 0.07, respectively).

Table 3 presents the adjusted relative risk (RR) for hospital admission prior to propensity score matching. After controlling for all covariates, the adjusted RR for Grade 1 patients who did not receive HOT compared to the reference group (those who did receive HOT) was 1.12 (95% CI, 1.01–1.60). The RR for Grade 2 patients was 0.96, but this difference was not statistically significant. In Grade 3 or No grade, the adjusted RRs for patients who did not receive HOT were less than one (RR, 0.74; 95% CI, 0.58–0.93; RR, 0.65; 95% CI, 0.60–0.70, respectively).

1  
2  
3  
4 After propensity score matching, the adjusted RR for Grade 1 patients who did not receive  
5 HOT was 1.65 (95% CI, 1.25–2.18); in Grade 2 patients, the adjusted RR was 1.07 (95% CI,  
6 0.80–1.43); in Grade 3 patients, the adjusted RR was 0.72 (95% CI, 0.51–1.02); and in  
7 patients without a grade, the adjusted RR was 0.73 (95% CI, 0.62–0.86) (Table 4).  
8  
9  
10  
11  
12  
13

## 14 Discussion

15  
16  
17 We found that HOT was associated with a 27% decreased risk of hospitalization in Grade 1  
18 COPD patients ( $FEV_1 \leq 25\%$  or  $Pa,O_2 \leq 55$  mmHg) prior to propensity score matching and a  
19 65% decreased risk after matching. However, apart from Grade 1 patients, the use of HOT  
20 did not show a statistically significant association with hospital admission prior to or after  
21 matching in Grade 2 patients. Also, in Grade 3 or No grade COPD patients ( $FEV_1 \leq 40\%$  or  
22  $Pa,O_2 \leq 65$  mmHg;  $FEV_1$  or  $Pa,O_2 = \text{unknown}$ ), HOT was associated with an increased risk of  
23 hospital admission prior to propensity score matching and in the case of No grade patients,  
24 HOT was still associated with an increased risk of admission after propensity score matching.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 In Korea, HOT can be prescribed by a pulmonologist as well as an internist and a thoracic  
39 surgery specialist through only a one time test of arterial blood gas analysis; similar to the  
40 criteria that most countries use for home oxygen therapy, the indications of HOT for  
41 reimbursement are patients with  $Pa,O_2$  less than or equal to 55mmHg or with  $SpO_2$  less than  
42 or equal to 88%. Patients with  $Pa,O_2$  between 56 and 60mmHg or  $SpO_2$  below 89%, must  
43 also have congestive heart failure, polycythemia (hematocrit > 55%), or pulmonary  
44 hypertension to qualify during the stable period after 3 months of internal treatment.  
45 Physicians can prescribe patients with Grade 1 or Grade 2 respiratory impairment without  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1  
2  
3  
4 conducting any other tests. If patients without indication of such grade receives HOT  
5 prescriptions, it means that the patient was seen by a physician under the COPD code but that  
6 the patient did not fill out the necessary form to receive an assigned grade. Hence the  
7 patient's clinical status fits the indications for HOT prescription, meaning that these patients  
8 may in actuality, have any of the grades described above, including Grade 1. Therefore, in the  
9 case of patients without a grade, the use of HOT means that the patients who use such HOT  
10 may have conditions that are clinically more severe than those who do not use HOT.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Our results are comparable to the findings of previous studies. We could not distinguish  
21 patient's status between Pa,O<sub>2</sub> and FEV<sub>1</sub>% predicted. We could only infer patients' Pa,O<sub>2</sub>,  
22 FEV<sub>1</sub> or shortness of breath with respiratory impairment grade. However, for patients with  
23 Pa,O<sub>2</sub> ≤ 55 mmHg or predicted FEV<sub>1</sub> ≤ 25% of grade 1, use of HOT was associated with a  
24 reduced risk of hospital admission. Most previous studies have showed a consistent tendency  
25 in patients with severe hypoxemia (Pa,O<sub>2</sub> < 8.0 kPa) in which HOT was associated with  
26 decreased hospital admissions. However, Ringbaek et al. found that home oxygen therapy did  
27 not reduce hospitalization in patients with moderate hypoxemia (Pa,O<sub>2</sub> > 8.0 kPa)[15]. In  
28 addition, many previous studies have found that FEV<sub>1</sub> predicted could be a predictor of acute  
29 exacerbation hospitalization [20-22]. One recent paper suggested that oxygen use outside the  
30 National Institute for Health and Care Excellence (NICE) guidance did not appear to prevent  
31 admissions[23] and FEV<sub>1</sub> was the only significant predictor of readmission[16]. In South  
32 Korea, although HOT is used according to NICE guidelines, HOT was not associated with  
33 decreased risk of hospital admission even in Grade 2 (Pa,O<sub>2</sub> 56-60mmHg or predicted FEV<sub>1</sub> ≤  
34 30%). In Grade 3 or No grade patients, admission to hospitals was more likely in HOT  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

1  
2  
3  
4 users prior to matching instead, and after matching, there was no statistically significant  
5  
6 difference in Grade 3 patients. There are two possible explanations regarding this result. One  
7  
8 is that because admission for exacerbation is more common in severe COPD[24] patients and  
9  
10 in oxygen users[25], hospital admissions are more frequently expected in HOT users if  
11  
12 patients' severity is unequal as they have more severe lung disease. The second possibility  
13  
14 may be explained through residual confounding. Garcia-Aymerich J. et al. showed that the  
15  
16 risks of re-admission was high in LTOT users after adjustment for severity variables such as  
17  
18 FEV<sub>1</sub> or Pa,O<sub>2</sub>[26]. The authors explained these paradoxical results using residual  
19  
20 confounding, that the excess risk of COPD re-admission associated with medical care related  
21  
22 factors might be partially due to confounding by indication. Our finding supports that HOT use  
23  
24 reduces hospitalization in COPD patients with severe hypoxemia (Pa,O<sub>2</sub> ≤55 mmHg) and a  
25  
26 predicted FEV<sub>1</sub> of ≤25%. However, although HOT may improve quality of life and help  
27  
28 breathing during activities in COPD patients without severe hypoxemia, use of HOT should  
29  
30 be considered to prevent hospital admissions in COPD patients with Pa,O<sub>2</sub>>55mmHg or a  
31  
32 predicted FEV<sub>1</sub>>25% . We need to at least conduct further research about cost-effectiveness  
33  
34 for HOT use in these patients and then, if necessary, require modification of the criteria for  
35  
36 HOT prescription.  
37  
38  
39  
40  
41  
42

43  
44 This study has several limitations. First, because we used claims data, which are based on  
45  
46 information in the KNHIS, we were not able to assess some factors that could potentially  
47  
48 influence hospital admissions. For example, we had no data on smoking history, body mass  
49  
50 index, health behaviors, use of systematic corticosteroids, laboratory results, etc. Second, we  
51  
52 categorized respiratory impairment into four respiratory disability grades, as determined by  
53  
54 FEV<sub>1</sub>, Pa,O<sub>2</sub>, and dyspnea. Therefore, we did not use quantitative FEV<sub>1</sub> or Pa,O<sub>2</sub> values,  
55  
56

1  
2  
3  
4 instead estimating a patient's hypoxemic status. Especially in the No grade group, it is  
5  
6 possible that patients with various severities have been mixed together. The third limitation is  
7  
8 the accuracy of our COPD diagnosis. The accuracy of diagnoses in KNHIS claims data is  
9  
10 roughly 70%[27]. To increase accuracy, a review of all prescriptions would be required.  
11  
12 Unfortunately, we could not perform such a review here. However, the accuracy of COPD  
13  
14 diagnoses in this study may have been compromised. The fourth limitation involves the  
15  
16 definition of newly diagnosed patients. In this study, newly diagnosed patients were defined  
17  
18 as those who did not have COPD claims in 2002–2004 but did have a COPD claim in 2005.  
19  
20 Thus, patients diagnosed prior to 2002 who did not utilize COPD-related medical services in  
21  
22 2002–2004 may have been included in the sample. The final limitation is related to patterns  
23  
24 of HOT use. Although all of our study subjects used HOT in or after 2006 and we adjusted  
25  
26 for the number of hospital admission at baseline, because of considering hypothesis in  
27  
28 previous studies that an effect of oxygen therapy in patients who start home oxygen therapy  
29  
30 as outpatients are less likely to be derived from a “regression to the mean phenomenon”[12],  
31  
32 we did not know the duration of usage per day, whether use was continuous or non-  
33  
34 continuous, or whether patient compliance was good.  
35  
36  
37  
38  
39

40  
41 Despite these limitations, our study has several strengths. First, we analyzed COPD  
42  
43 patients using nationwide claims data and conducted a longitudinal population-based  
44  
45 prospective analysis based on claims from 2005 to 2012. Our study population was relatively  
46  
47 large and our follow-up period was relatively long compared to previous studies evaluating  
48  
49 the association between oxygen therapy and hospitalization[28,29]. Second, we were able to  
50  
51 increase the homogeneity of our study sample by identifying patients who were newly  
52  
53 diagnosed in 2005. We could observe the progression of their disease over time via hospital  
54  
55

1  
2  
3  
4 admissions. Finally, we made an effort to accurately determine the net effect of HOT via  
5  
6 propensity score matching.  
7  
8

9  
10 In conclusion, HOT reduces hospital admission risk in COPD patients with severe  
11  
12 hypoxemia or a predicted FEV<sub>1</sub> of  $\leq 25\%$ . However, except for these patients, HOT use is  
13  
14 not associated with hospital admissions, or an increase in the likeliness of hospital admission.  
15  
16 Still, further research on cost-effectiveness of HOT in patients who does not meet the  
17  
18 indication for HOT is needed, even in patients with Pa,O<sub>2</sub> 56-60 mmHg or a predicted FEV<sub>1</sub>  
19  
20 of 26-30% who meet the indication.  
21  
22  
23  
24  
25  
26  
27

## 28 **Acknowledgement**

29  
30 **Financial Disclosure:** The entire study was conducted without external funding.  
31  
32

33  
34 **Conflicts of Interests:** None of the authors have any conflicts of interest associated with this  
35  
36 study.  
37  
38

39  
40 **Contribution :** Cho KH and Park EC carried out constructing study design, Cho KH and  
41  
42 Nam CM carried out analyzing data, Cho KH, Park EC, and KimYS interpreted results, Kim  
43  
44 YS was scientific advisor, Park EC guided and directed this study Cho KH and Kim TH  
45  
46 wrote manuscript and Kim SJ and Han KT was clinical investigators.  
47  
48  
49  
50

51  
52 **Data sharing:** Additional data is available by emailing the corresponding author.  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Jung JY, Kang YA, Park MS, Oh YM, Park EC, Kim HR, et al. Chronic obstructive lung disease-related health care utilisation in Korean adults with obstructive lung disease. *Int J Tuberc Lung Dis.* 2011;15: 824-829.
2. Halpin DM, Miravittles M. Chronic obstructive pulmonary disease: the disease and its burden to society. *Proc Am Thorac.* 2006;3: 619-623.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 2006;3: e442.
4. Coleta KD, Silveira LV, Lima DF, Rampinelli EA, Godoy I, Godoy I. Predictors of first-year survival in patients with advanced COPD treated using long-term oxygen therapy. *Respir Med.* 2008;102: 512-518.
5. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Espana PP, et al. Predictors of mortality in patients with stable COPD. *J Gen Intern Med.* 2008;23: 1829-1834.
6. Law S, Boyd S, Macdonald J, Raeside D, Anderson D. Predictors of survival in patients with chronic obstructive pulmonary disease receiving long-term oxygen therapy. *BMJ Support Palliat Care* Published Online First. 2014;25 Mar 2014. doi: 10.1136/bmjspcare-2012-000432.

- 1  
2  
3  
4 7. Eaton T, Lewis C, Young P, Kennedy Y, Garrett JE, Kolbe J. Long-term oxygen  
5 therapy improves health-related quality of life. *Respir Med.* 2004;98: 285-293.  
6  
7  
8
- 9  
10 8. Medical Research Council. Long term domiciliary oxygen therapy in chronic hypoxic  
11 cor pulmonale complicating chronic bronchitis and emphysema. Report of the  
12 Medical Research Council Working Party. *Lancet.* 1981;28: 681-686.  
13  
14  
15  
16  
17
- 18 9. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in  
19 hypoxemia chronic obstructive lung disease. *Ann Intern Med.* 1980;93: 391-398.  
20  
21  
22  
23  
24
- 25 10. Korea Ministry of Government Legislation. Welfare of Disabled Person Act (2011-91).  
26 [http://www.mw.go.kr/front\\_new/policy/index.jsp?PAR\\_MENU\\_ID=06&MENU\\_ID=](http://www.mw.go.kr/front_new/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=063701&PAGE=11)  
27 [063701&PAGE=11.](http://www.mw.go.kr/front_new/policy/index.jsp?PAR_MENU_ID=06&MENU_ID=063701&PAGE=11)  
28  
29  
30  
31  
32
- 33 11. Clini E, Vitacca M, Foglio K, Simoni P, Ambrosino N. Long-term home care  
34 programmes may reduce hospital admissions in COPD with chronic hypercapnia. *Eur*  
35 *Respir J.* 1996;9: 1605-1610.  
36  
37  
38  
39  
40
- 41 12. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce  
42 hospitalisation in hypoxaemic chronic obstructive pulmonary disease? *Eur Respir J.*  
43 *2002;20: 38-42.*  
44  
45  
46  
47  
48
- 49 13. Roselle S, D'Amico FJ. The effect of home respiratory therapy on hospital  
50 readmission rates of patients with chronic obstructive pulmonary disease. *Respir Care.*  
51  
52  
53  
54  
55



- 1  
2  
3  
4 1982;27: 1194-1199.  
5  
6  
7  
8 14. Stewart BN, Hood CI, Block AJ. Long-term results of continuous oxygen therapy at  
9 sea level. *Chest*. 1975;68: 486-492.  
10  
11  
12  
13  
14 15. Ringbaek TJ, Fabricius P, Lange P. The effect of home oxygen therapy on  
16 hospitalization in moderate hypoxaemic COPD. *Chron Respir Dis*. 2005;2: 107-108.  
17  
18  
19  
20  
21 16. Turner AM, Sen S, Steeley C, Khan Y, Sweeney P, Richards Y, et al. Evaluation of  
22 oxygen prescription in relation to hospital admission rate in patients with chronic  
23 obstructive pulmonary disease. *BMC Pulm Med*. 2014;5: 127. doi: 110.1186/1471-  
24 2466-1114-1127.  
25  
26  
27  
28  
29  
30  
31  
32 17. Kim J, Kim K, Kim Y, Yoo KH, Lee CK, Yoon HK, et al. The association between  
33 inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed  
34 COPD patients. *Respir Med*. 2014;108: 153-161.  
35  
36  
37  
38  
39  
40  
41 18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding  
42 algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.  
43 *Med care*. 2005;43: 1130-1139.  
44  
45  
46  
47  
48  
49 19. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of  
50 Confounding in Observational Studies. *Multivariate Behav Res*. 2011;46: 399-424.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Bowler RP, Kim V, Regan E, Williams AA, Santorico SA MB, Lynch DA, Hokanson JE, Washko GR, Bercz P, Soler X, Marchetti N, Criner GJ, Ramsdell J, Han MK, Demeo D, Anzueto A, Comellas A, Crapo JD, Dransfield M, Wells JM, Hersh CP, MacIntyre N, Martinez F, Nath HP, Niewoehner D, Sciurba F, Sharafkhaneh A, Silverman EK, van Beek EJ, Wilson C, Wendt C, Wise RA; COPDGene investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD. *Chest*. 2014;146: 941-950.
21. Mohktar MS, Redmond SJ, Antoniadis NC, Rochford PD, Pretto JJ, Basilakis J, et al. Predicting the risk of exacerbation in patients with chronic obstructive pulmonary disease using home telehealth measurement data. *Artif Intell Med*. 2015;63: 51-59.
22. Kon SS, Jones SE, Schofield SJ, Banya W, Dickson MJ, Canavan JL, et al. Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study. *Thorax*. 2015;In press: doi: 10.1136/thoraxjnl-2015-207046.
23. Turner AM, Sen S, Steeley C, Khan Y, Sweeney P, Richards Y, et al. Evaluation of oxygen prescription in relation to hospital admission rate in patients with chronic obstructive pulmonary disease. *BMC Pulm Med*. 2014;14.
24. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *M Engl J Med*. 2010;363: 1128-1138.

- 1  
2  
3  
4 25. Bahadori K, FitzGerald JM, Levy RD, Fera T, Swiston J. Risk factors and outcomes  
5 associated with chronic obstructive pulmonary disease exacerbations requiring  
6 hospitalization. *Can Respir J*. 2009;16: e43-49.  
7  
8  
9  
10  
11  
12 26. Garcia-Aymerich J, Marrades RM, Monsó E, Barreiro E, Farrero E, Antó JM.  
13 Paradoxical results in the study of risk factors of chronic obstructive pulmonary  
14 disease (COPD) re-admission. *Respir Med*. 2004;98: 851-857.  
15  
16  
17  
18  
19  
20  
21 27. Kim RY. Introduction of national patients sample data of Korean Health Insurance  
22 Review and Assessment Service. *Forum*. 2011.  
23  
24  
25  
26  
27 28. Kessler R, Faller M, Fourgaut G, Menecier B, Weitzenblum E. Predictive factors of  
28 hospitalization for acute exacerbation in a series of 64 patients with chronic  
29 obstructive pulmonary disease. *Am J Respir Crit Care Med*. 1999;159: 158-164.  
30  
31  
32  
33  
34  
35  
36 29. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce  
37 hospitalisation in hypoxaemic chronic obstructive pulmonary disease? *Eur Respir J*.  
38 2002;20: 38-42.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Baseline characteristics of the study sample, stratified according to use of home oxygen therapy

Characteristics	Pre-match (N=36,761)			Post-match (1:1; N=2,478)		
	Yes, n (%)	No, n (%)	P-value	Yes, n (%)	No, n (%)	P-value
Age (years), mean (SD)	67.1 (9.6)	63.8 (12.0)	<0.0001	67.4 (9.7)	68.0 (9.9)	0.14
Sex						
Male	964 (4.7)	19,353 (95.3)	<0.0001	884 (49.2)	912 (50.8)	0.21
Female	367 (2.2)	16,078 (97.8)		355 (52.0)	327 (48.0)	
Health insurance type						
National health insurance	1,279 (3.8)	32,645 (96.2)	<0.0001	1,188 (50.5)	1,163 (49.5)	0.02
Medical aid	51 (1.8)	2,786 (98.2)		51 (40.2)	76 (59.8)	
Charlson comorbidity index *						
0	692 (6.5)	9,983 (93.5)	<0.0001	628 (48.4)	670 (51.6)	0.13
1	62 (5.7)	1,021 (94.3)		57 (47.1)	64 (52.9)	
≥2	576 (2.3)	24,427 (97.7)		554 (52.3)	505 (47.7)	
ICU use						
Yes	11 (6.9)	148 (93.1)	<0.0001	9 (39.1)	12 (60.9)	0.30
No	1,319 (3.6)	35,283 (96.4)		1,230 (50.1)	1,225 (49.9)	
Number of hospital admission						
0	1,147 (3.5)	31,923 (96.5)	<0.0001	1,067 (51.5)	1,004 (48.5)	0.002
1	127 (4.9)	2,486 (95.1)		119 (40.6)	174 (59.4)	
≥2	56 (5.2)	1,022 (94.8)		53 (46.5)	61 (53.5)	
Respiratory impairment rating						
Grade 1 (FEV <sub>1</sub> %≤25 or Pa,O <sub>2</sub> ≤55 mmHg)	163 (43.2)	214 (56.8)	<0.0001	91 (43.1)	120 (56.9)	0.001
Grade 2 (FEV <sub>1</sub> %≤30 or Pa,O <sub>2</sub> ≤60 mmHg)	121 (35.6)	219 (64.4)		102 (55.7)	81 (44.3)	
Grade 3 (FEV <sub>1</sub> %≤40 or Pa,O <sub>2</sub> ≤65 mmHg)	110 (26.6)	304 (73.4)		110 (61.1)	70 (38.9)	
No Grade	936 (2.6)	34,694 (97.4)		936 (49.2)	968 (50.8)	

SD, standard deviation; ICU, intensive care unit.

\*, calculated comorbidity component; subtracted age scores.

Table 2. Incidence density for hospital admission according to use of home oxygen therapy

Respiratory Impairment Rating <sup>†</sup>	Pre-match				Post-match (1:1)				
	Yes	No	Yes	No	Yes	No	Yes	No	
	N=1,330	N=35,431	ID*	ID*	N=1,239	N=1,239	ID*	ID*	
Grade 1	Total number of hospital admission	416	748	0.60	1.01	244	319	0.62	0.79
	Person-years	694.1	743.3			390.8	406.0		
Grade 2	Total number of hospital admission	358	601	0.61	0.63	291	128	0.59	0.37
	Person-years	585.6	953.4			495.9	341.4		
Grade 3	Total number of hospital admission	245	672	0.47	0.46	245	81	0.47	0.23
	Person-years	517.8	1455.4			517.8	348.3		
No Grade	Total number of hospital admission	1409	9286	0.34	0.05	1409	322	0.34	0.07
	Person-years	4123.0	18455.3			4123.0	4837.3		

\*ID, Incidence Density; calculated total number of hospital admissions divided into sum of person-years.

<sup>†</sup>, Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>o</sub>2 ≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤ 30% predicted or Pa<sub>o</sub>2 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>o</sub>2 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>o</sub>2 unknown .

Table 3. Relative Risk for hospital admission, stratified respiratory disability grade calculated using negative binomial regression model

Characteristics	Relative Risk (95% CI)							
	Grade 1		Grade 2		Grade 3		No Grade	
Age (years)	1.002	(0.993-1.010)	0.992	(0.983-1.001)	1.010	(0.993-1.021)	1.006	(1.004-1.009)***
Sex								
Male	1.06	(0.87-1.29)	1.25	(0.96-1.62)	0.94	(0.75-1.18)	1.16	(1.10-1.23)***
Female	1.00		1.00		1.00		1.00	
Health insurance type								
National health insurance	1.00	(0.80-1.25)	0.94	(0.75-1.17)	0.60	(0.49-0.75)***	0.69	(0.65-0.73)***
Medical aid	1.00		1.00		1.00		1.00	
Home oxygen therapy								
Yes	1.00		1.00		1.00		1.00	
No	1.27	(1.01-1.60)*	0.96	(0.75-1.22)	0.74	(0.58-0.93)*	0.65	(0.60-0.70)***
Charlson comorbidity index <sup>†</sup>								
0	1.00		1.00		1.00		1.00	
1	0.86	(0.66-1.13)	1.00	(0.72-1.39)	0.82	(0.57-1.17)	1.00	(0.93-1.07)
≥2	1.12	(0.84-1.49)	1.11	(0.81-1.53)	0.90	(0.67-1.21)	1.11	(1.02-1.21)*
ICU use								
Yes	1.13	(0.74-1.70)	1.05	(0.42-2.59)	0.31	(0.09-1.09)	1.02	(0.82-1.27)
No	1.00		1.00		1.00		1.00	
Number of hospital admission								
0	1.00		1.00		1.00		1.00	
1	1.65	(1.29-2.11)***	1.45	(1.12-1.88)**	1.24	(0.98-1.57)	1.69	(1.58-1.81)***
≥2	1.73	(1.34-2.24)***	1.48	(1.11-1.96)**	1.65	(1.28-2.12)***	2.04	(1.88-2.21)***

\*, P-value<0.05; \*\*, P-value<0.01; \*\*\*, P-value<0.001.

Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>o</sub>2≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤ 30% predicted or Pa<sub>o</sub>2 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>o</sub>2 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>o</sub>2 unknown

<sup>†</sup>, calculated comorbidity component; subtracted age scores.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Table 4. Relative risk for hospital admission after propensity score matching calculated using negative binomial regression model

Characteristics	Relative Risk (95% CI)			
	Grade 1	Grade 2	Grade 3	No Grade
Home oxygen therapy				
Yes	1.00	1.00	1.00	1.00
No	1.65 (1.25-2.18) <sup>***</sup>	1.07 (0.80-1.43)	0.72 (0.51-1.02)	0.73 (0.62-0.86) <sup>***</sup>

<sup>\*</sup>, P-value<0.05; <sup>\*\*</sup>, P-value<0.01; <sup>\*\*\*</sup>, P-value<0.001

Grade 1 was defined patients with chronic respiratory failure requiring oxygen therapy and an FEV<sub>1</sub> ≤25% predicted or resting Pa<sub>a</sub>O<sub>2</sub> ≤55 mmHg (room air); Grade 2 was defined patients with dyspnea when walking at home and an FEV<sub>1</sub> ≤ 30% predicted or Pa<sub>a</sub>O<sub>2</sub> 56-60 mmHg (room air); Grade 3 was defined patients with dyspnea when walking at their own pace on the ground level and FEV<sub>1</sub> ≤40% predicted or Pa<sub>a</sub>O<sub>2</sub> 61-65 mmHg (room air); No Grade was defined FEV<sub>1</sub> or Pa<sub>a</sub>O<sub>2</sub> unknown

Peer review only